HemoShear Therapeutics has been invited to present at several investor conferences this month. During these virtual meetings, HemoShear will showcase its HST5040 clinical program and the company’s REVEAL-Tx™ drug discovery platform to a range of institutional investors and potential strategic partners.
HemoShear will present at the following virtual conferences:
“HemoShear appreciates these opportunities to update institutional investors and prospective partners on progress of our proprietary rare disease programs made possible by our drug discovery platform,” said Jim Powers, Chairman and CEO of HemoShear. “These conferences are an excellent opportunity to reach a targeted audience and promote dialogue with institutional investors and potential strategic partners. We look forward to making progress in identifying the right partners to support the advancement of HemoShear’s pipeline.”
HemoShear has received clearance from the FDA to conduct a phase 2 clinical study of its oral drug HST5040 in patients with methylmalonic acidemia (MMA) and propionic acidemia (PA). MMA and PA are rare genetic disorders caused by the deficiency of certain enzymes required to metabolize amino acids. The diseases result in the rapid buildup of life-threatening metabolites that can lead to severe organ damage, seizures, developmental deficits, and premature death. HemoShear’s phase 2 clinical study, HERO (HElp Reduce Organic Acids), is designed to enroll at least 12 patients with MMA and PA at select children’s hospitals in the United States.
HemoShear Therapeutics, Inc.
501 Locust Avenue
Charlottesville, Virginia 22902